ReviewThe Prostate2026
Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.
Review in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen positron emission tomography (PSMA-PET) is reshaping nodal staging in prostate cancer by detecting regional lymph node metastases with greater accuracy than conventional imaging. This has created a new cohort of patients with N1M0 disease detectable only on advanced imaging, raising important questions regarding prognosis, treatment intensification and the applicability of historical management paradigms derived from conventional imaging. The aim of this review is to consider de novo N1M0 management on PSMA-PET and current evidence.
methodsA comprehensive review of the literature was performed using Medline, PubMed and Web of Science. Search terms included combinations of "N1M0", "prostate cancer", "PSMA", "PET", "lymph node" and "metastasis". English-language studies and relevant reference lists were reviewed, with interpretation focused on diagnostic performance, stage migration and management implications of PSMA-PET-detected nodal disease.
resultsPSMA-PET outperforms conventional imaging for nodal staging, improving diagnostic confidence and frequently altering management. However, sensitivity for small-volume nodal disease remains imperfect, limiting exclusion of microscopic metastases. Emerging data suggest PSMA-PET drives stage migration whilst influencing use of surgery, radiotherapy and systemic therapy to better tailor treatment fields. However, high-level prospective evidence demonstrating improved long-term oncological outcomes remains limited.
conclusionsPSMA-PET is a practice-changing staging modality in N1M0 prostate cancer, but whether earlier detection and treatment escalation translate into meaningful survival benefit remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.